Cristina Nanni

List of Publications by Year
in descending order

205 papers	8,850 citations	36303 51 h-index	46799 89 g-index
211 all docs	211 docs citations	211 times ranked	8432 citing authors

#	Article	IF	Citations
1	Spine Infections: The Role of Fluorodeoxyglucose Positron Emission Tomography (FDG PET) in the Context of the Actual Diagnosis Guideline. Current Medical Imaging, 2022, 18, 216-230.	0.8	2
2	Standardization of ¹⁸F-FDGâ€“PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 116-125.	1.6	85
3	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1005-1015.	6.4	35
4	Imaging Techniques in Staging and Early Phases. , 2021, , 53-66.		0
5	18F-FDG PET-CT in Treatment Response Evaluation: Multiple Myeloma. , 2021, , 395-401.		0
6	The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. Cancers, 2021, 13, 1575.	3.7	4
7	Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. European Journal of Radiology, 2021, 141, 109793.	2.6	16
8	[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 390-409.	6.4	7
9	Skeletal Survey in Multiple Myeloma: Role of Imaging. Current Medical Imaging, 2021, 17, 956-965.	0.8	3
10	PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. Seminars in Nuclear Medicine, 2021, 51, 621-632.	4.6	17
11	Radiological and Nuclear Medicine Imaging of Multiple Myeloma. , 2021, , .		0
12	The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma. Seminars in Nuclear Medicine, 2021, , .	4.6	6
13	[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imagingâ€”version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 579-591.	6.4	39
14	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 5406.	4.1	13
15	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers, 2020, 12, 2532.	3.7	17
16	Predictive Role of MRI and 18F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study. Cancers, 2020, 12, 659.	3.7	8
17	Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3058-3065.	6.4	8
18	Benign albeit glycolytic: MCT4 expression and lactate release in giant cell tumour of bone. Bone, 2020, 134, 115302.	2.9	4

#	Article	IF	Citations
19	The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lungÂcancer (NSCLC). Clinical and Translational Imaging, 2020, 8, 29-38.	2.1	0
20	PET-FDG: Impetus. Cancers, 2020, 12, 1030.	3.7	13
21	Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20â€‰ng/mL. Nuclear Medicine Communications, 2020, 41, 1178-1182.	1.1	0
22	Learned Deep Radiomics for Survival Analysis with Attention. Lecture Notes in Computer Science, 2020, , 35-45.	1.3	1
23	PET/CT with Standard Non-FDG Tracers in Multiple Myeloma. , 2019, , 93-97.		4
24	The Issue of Interpretation. , 2019, , 99-104.		1
25	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	10.7	338
26	Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma. PET Clinics, 2019, 14, 383-389.	3.0	9
27	Multi-Imaging Investigation to Evaluate the Relationship between Serum Cystatin C and Features of Atherosclerosis in Non-ST-Segment Elevation Acute Coronary Syndrome. Applied Sciences (Switzerland), 2019, 9, 657.	2.5	0
28	Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study. Cancers, 2019, 11, 713.	3.7	10
29	Sclerosing Angiomatoid Nodular Transformation of the Adrenal Gland: A Case Report of a Novel Histopathological Entity. Journal of the Endocrine Society, 2019, 3, 1207-1213.	0.2	4
30	Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1661-1671.	6.4	8
31	Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients. Leukemia and Lymphoma, 2019, 60, 2247-2254.	1.3	4
32	Interest of Pet Imaging in Multiple Myeloma. Frontiers in Medicine, 2019, 6, 69.	2.6	34
33	The role of 18F-FDG PET/CT in soft tissue sarcoma. Nuclear Medicine Communications, 2019, 40, 626-631.	1.1	27
34	Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 194-205.	6.4	45
35	Stateâ€ofâ€theâ€art imaging techniques in the management of preoperative staging and reâ€staging of prostate cancer. International Journal of Urology, 2019, 26, 18-30.	1.0	16
36	Hybrid Imaging for Gynecologic Malignancies. , 2019, , 881-898.		0

#	Article	IF	Citations
37	Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. Leukemia and Lymphoma, 2018, 59, 2990-2993.	1.3	8
38	A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. Future Oncology, 2018, 14, 1101-1115.	2.4	8
39	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian) Tj ETQq1 1 0.784314 rgBT /Over 712-719.	6.4	95
40	FDG-PET/CT Guided Biopsy in Angiosarcoma of Bone. Clinical Nuclear Medicine, 2018, 43, e48-e49.	1.3	4
41	Vertebral Fractures of Unknown Origin: Role of Computed Tomography-Guided Biopsy. International Journal of Spine Surgery, 2018, 12, 673-679.	1.5	11
42	In Vivo Imaging of Inflammation and Infection. Contrast Media and Molecular Imaging, 2018, 2018, 1-2.	0.8	1
43	Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2139-2146.	6.4	38
44	Nuclear Medicine Imaging of Prostate Cancer in the Elderly. Seminars in Nuclear Medicine, 2018, 48, 541-547.	4.6	6
45	Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 305-312.e1.	1.9	19
46	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. Blood, 2018, 132, 257-257.	1.4	20
47	Prostate cancer imaging and therapy. , 2018, , .		0
48	Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?. Journal of Nuclear Cardiology, 2017, 24, 746-749.	2.1	31
49	Report of the 6th International Workshop on PET in lymphoma. Leukemia and Lymphoma, 2017, 58, 2298-2303.	1.3	21
50	A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?. American Journal of Roentgenology, 2017, 209, 152-158.	2.2	29
51	Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1878-1887.	6.4	9
52	Therapy assessment in multiple myeloma with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 111-117.	6.4	14
53	Prostate Cancer Imaging and Therapy. PET Clinics, 2017, 12, i.	3.0	0
54	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncology, The, 2017, 18, e206-e217.	10.7	394

#	Article	IF	Citations
55	Prostate Cancer Imaging in the Era of Molecular Medicine. PET Clinics, 2017, 12, xi.	3.0	1
56	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 Biochemically Recurrent Prostate Cancer. Journal of Urology, 2017, 197, 676-683.	0.4	165
57	The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 215-223.	6.4	52
58	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
59	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
60	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 749-775.		0
61	Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. Journal of Nuclear Medicine, 2016, 57, 61S-66S.	5.0	35
62	PET Tracers Beyond FDG in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 507-521.	4.6	62
63	PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2103-2104.	6.4	7
64	The Possible Role of PET Imaging Toward Individualized Management ofÂBone and Soft Tissue Malignancies. PET Clinics, 2016, 11, 285-296.	3.0	7
65	18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1601-1610.	6.4	204
66	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 414-421.	6.4	92
67	18F-FDG PET/CT for Bone and Soft Tissue Biopsy. , 2016, , 87-93.		0
68	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2016, , 1-27.		0
69	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	1.4	0
70	11C-Meta-Hydroxyephedrine. Clinical Nuclear Medicine, 2015, 40, e96-e103.	1.3	14
71	68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. Clinical Nuclear Medicine, 2015, 40, e132-e133.	1.3	9
72	18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse. Clinical Nuclear Medicine, 2015, 40, e386-e391.	1.3	118

#	Article	IF	Citations
73	Cardiac resynchronization therapy and cardiac sympathetic function. European Journal of Clinical Investigation, 2015, 45, 792-799.	3.4	18
74	Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment. Nanomedicine, 2015, 10, 3483-3494.	3.3	57
75	The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1068-1073.	2.0	46
76	FDG PET/CT for bone and soft-tissue biopsy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1333-1334.	6.4	10
77	PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4384-4390.	7.0	140
78	Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. Nuclear Medicine and Biology, 2015, 42, 858-863.	0.6	11
79	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. Blood, 2015, 126, 5009-5009.	1.4	0
80	Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study. PLoS ONE, 2014, 9, e108112.	2.5	91
81	First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. Archivio Italiano Di Urologia Andrologia, 2014, 86, 239.	0.8	8
82	Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice. Cancer Biology and Therapy, 2014, 15, 1219-1225.	3.4	21
83	Anti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease. Journal of Nuclear Medicine, 2014, 55, 1986-1992.	5.0	138
84	Nuclear medicine in urological cancers: what is new?. Future Oncology, 2014, 10, 2061-2072.	2.4	3
85	Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using 124I PET/CT Sequential Scans for 131I Treatment Planning. Clinical Nuclear Medicine, 2014, 39, e367-e374.	1.3	28
86	Usefulness of 64Cu-ATSM in Head and Neck Cancer. Clinical Nuclear Medicine, 2014, 39, e59-e63.	1.3	36
87	First Case of ¹⁸F-FACBC PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse after Radical Prostatectomy for Prostate Cancer and Negative ¹¹C-Choline PET/CT: New Imaging Techniques May Expand Pioneering Approaches. Urologia Internationalis, 2014, 92, 242-245.	1.3	19
88	The Use of Gallium-68 Labeled Somatostatin Receptors in PET/CT Imaging. PET Clinics, 2014, 9, 323-329.	3.0	45
89	18F-FDG PET/CT impact on testicular tumours clinical management. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 668-673.	6.4	60
90	FDG PET/CT in autoimmune pancreatitis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1264-1265.	6.4	5

#	Article	IF	Citations
91	Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series. BMC Research Notes, 2014, 7, 32.	1.4	32
92	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1617-1623.	6.4	79
93	FDG and other radiopharmaceuticals in the evaluation of liver lesions. Clinical and Translational Imaging, 2014, 2, 115-127.	2.1	2
94	Performance of FDG PET/ceCT in the evaluation of patients with lung cancer. Biomedicine and Pharmacotherapy, 2014, 68, 219-223.	5.6	4
95	18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients. Clinical Genitourinary Cancer, 2014, 12, 106-110.	1.9	68
96	Positron Emission Tomography With Computed Tomographyâ€“Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e101-e104.	0.4	10
97	Reactive follicular lymphoid infiltrate: A new condition to exclude in patients with PET positivity inside the heart. Journal of Nuclear Cardiology, 2014, 21, 402-405.	2.1	0
98	Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study. Current Radiopharmaceuticals, 2014, 7, 107-114.	0.8	3
99	¹¹C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications. Current Radiopharmaceuticals, 2014, 7, 79-83.	0.8	5
100	Molecular Imaging and Tumoral Antigen Targeting. Medical Radiology, 2014, , 863-870.	0.1	0
101	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 365-84.	1.0	109
102	Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1356-1364.	6.4	43
103	18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1190-1196.	6.4	63
104	Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 642-643.	6.4	0
105	Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 11-17.	6.4	109
106	Usefulness of 11C-Choline Positron Emission Tomography for Genital Chlamydial Infection Assessment in a Balb/c Murine Model. Molecular Imaging and Biology, 2013, 15, 450-455.	2.6	3
107	Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice. Molecular Imaging and Biology, 2013, 15, 194-202.	2.6	12
108	11C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. Molecular Metabolism, 2013, 2, 153-160.	6.5	21

#	Article	IF	Citations
109	The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. Biomedicine and Pharmacotherapy, 2013, 67, 172-178.	5.6	10
110	Applications of Small Animal PET. Recent Results in Cancer Research, 2013, 187, 247-255.	1.8	1
111	The detection of disease relapse after radical treatment for prostate cancer. Nuclear Medicine Communications, 2013, 34, 831-833.	1.1	13
112	The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <0.5 ng/mL. Clinical Nuclear Medicine, 2013, 38, e342-e345.	1.3	63
113	PET/CT in the Management and Prognosis of Pancreatic Exocrine Tumors. Clinical Nuclear Medicine, 2013, 38, 33-34.	1.3	1
114	The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM). Clinical Nuclear Medicine, 2013, 38, e74-e79.	1.3	65
115	18F-FDG PET/CT for the Assessment of Disease Extension and Activity in Patients With Sarcoidosis. Clinical Nuclear Medicine, 2013, 38, e171-e177.	1.3	66
116	Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy. Clinical Cancer Research, 2012, 18, 796-807.	7.0	74
117	Feasibility of Carbidopa Premedication in Pediatric Patients: A Pilot Study. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 729-733.	1.0	11
118	18F-DOPA PET/CT in Neuroblastoma. Clinical Nuclear Medicine, 2012, 37, e73-e78.	1.3	63
119	F-18 FDG PET/CT Detects Muscle Involvement in Erdheim-Chester Disease. Clinical Nuclear Medicine, 2012, 37, 196-197.	1.3	11
120	Potential role of combined FDG PET/CT & contrast enhancement MRI in a rectal carcinoma model with nodal metastases characterized by a poor FDG-avidity. European Journal of Radiology, 2012, 81, 658-662.	2.6	3
121	PET/CT imaging in different types of lung cancer: An overview. European Journal of Radiology, 2012, 81, 988-1001.	2.6	132
122	Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. European Journal of Radiology, 2012, 81, e893-e896.	2.6	106
123	FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1538-1544.	6.4	76
124	Gallium-labelled peptides for imaging of inflammation. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 68-77.	6.4	38
125	Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1278-1283.	6.4	34
126	Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 57-71.	6.4	111

#	Article	IF	Citations
127	Value of FDG PET/CT in Patients with Treated Ovarian Cancer and Raised CA125 Serum Levels. Molecular Imaging and Biology, 2012, 14, 123-129.	2.6	41
128	Cellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in a rat model. Texas Heart Institute Journal, 2012, 39, 488-99.	0.3	16
129	Preclinical Studies with Small Animal PET. PET Clinics, 2011, 6, 71-77.	3.0	1
130	Present and future of PET and PET/CT in gynaecologic malignancies. European Journal of Radiology, 2011, 78, 12-20.	2.6	25
131	When Should F-18 FDG PET/CT Be Used Instead of 68Ga-DOTA-Peptides to Investigate Metastatic Neuroendocrine Tumors?. Clinical Nuclear Medicine, 2011, 36, 1109-1111.	1.3	5
132	I-123 MIBG Scintigraphy and 68Ga-DOTANOC PET/CT Negative But F-18 DOPA PET/CT Positive Pheochromocytoma. Clinical Nuclear Medicine, 2011, 36, 124-126.	1.3	9
133	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood, 2011, 118, 5989-5995.	1.4	445
134	Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5Âng/ml?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 55-63.	6.4	166
135	18F-FDG PET/CT detects systemic involvement in sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2102-2102.	6.4	6
136	Imaging with 11Carbon labelled PET tracers. Nuclear Medicine Communications, 2010, 31, 613-616.	1.1	3
137	68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 722-727.	6.4	107
138	Imaging with non-FDG PET tracers: outlook for current clinical applications. Insights Into Imaging, 2010, 1, 373-385.	3.4	13
139	Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. Molecular Imaging and Biology, 2010, 12, 616-625.	2.6	17
140	⁶⁸Ga-Citrate PET/CT for Evaluating Patients with Infections of the Bone: Preliminary Results. Journal of Nuclear Medicine, 2010, 51, 1932-1936.	5.0	118
141	Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-RasG12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging. Molecular Cancer Therapeutics, 2010, 9, 673-681.	4.1	27
142	⁶⁸Ga-DOTANOC PET/CT Allows Somatostatin Receptor Imaging in Idiopathic Pulmonary Fibrosis: Preliminary Results. Journal of Nuclear Medicine, 2010, 51, 1950-1955.	5.0	60
143	FDG-PET and PET/CT for Evaluating Soft Tissue Sarcomas. PET Clinics, 2010, 5, 341-347.	3.0	5
144	⁶⁸Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 669-673.	5.0	227

#	Article	IF	Citations
145	Molecular Imaging and Tumoural Antigen Targeting. Medical Radiology, 2010, , 871-878.	0.1	0
146	Non FDG PET. Clinical Radiology, 2010, 65, 536-548.	1.1	47
147	CB1 Signaling in Forebrain and Sympathetic Neurons Is a Key Determinant of Endocannabinoid Actions on Energy Balance. Cell Metabolism, 2010, 11, 273-285.	16.2	190
148	Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. Journal of Experimental and Clinical Cancer Research, 2010, 29, 173.	8.6	31
149	11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. Tumori, 2009, 95, 382-384.	1.1	28
150	Small Animal PET in Oncology: The Road from Bench to Bedside. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 277-285.	1.0	13
151	Influence of Trigger PSA and PSA Kinetics on ¹¹C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. Journal of Nuclear Medicine, 2009, 50, 1394-1400.	5.0	230
152	Functional and histopathological improvement of the postâ€infarcted rat heart upon myoblast cell grafting and relaxin therapy. Journal of Cellular and Molecular Medicine, 2009, 13, 3437-3448.	3.6	33
153	Positron-emission tomography in gynaecologic malignancies. Archives of Gynecology and Obstetrics, 2009, 280, 521-528.	1.7	16
154	Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 616-623.	6.4	11
155	Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1940-1943.	6.4	8
156	Small animal PET for the evaluation of an animal model of genital infection. Clinical Physiology and Functional Imaging, 2009, 29, 187-192.	1.2	10
157	A novel model of CCl4-induced cirrhosis with ascites in the mouse. Journal of Hepatology, 2009, 51, 991-999.	3.7	100
158	Synthesis and quality control of 68Ga citrate for routine clinical PET. Nuclear Medicine Communications, 2009, 30, 542-545.	1.1	38
159	Late FDG PET Normalization After Radioimmunotherapy in a Patient With Non-Hodgkin Lymphoma. Clinical Nuclear Medicine, 2009, 34, 777-778.	1.3	1
160	68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nuclear Medicine Communications, 2009, 30, 281-286.	1.1	89
161	11C-methionine vs. 18F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: preliminary results. In Vivo, 2009, 23, 105-10.	1.3	12
162	Could choline PET play a role in malignancies other than prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 216-218.	6.4	3

#	Article	IF	Citations
163	Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1431-1438.	6.4	254
164	Early relapse in a patient with Hodgkinâ€™s disease and negative interim FDG-PET. Annals of Nuclear Medicine, 2008, 22, 429-432.	2.2	6
165	Contouring Carcinomas by FDG-PET: Is the Role of Tumor Biology Underestimated?: In Regard to MacManus et al. (Int J Radiat Oncol Biol Phys 2008;71:2â€“4). International Journal of Radiation Oncology Biology Physics, 2008, 72, 303-304.	0.8	2
166	Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomedicine and Pharmacotherapy, 2008, 62, 667-671.	5.6	82
167	Applications of Small Animal Imaging with PET, PET/CT, and PET/MR Imaging. PET Clinics, 2008, 3, 243-250.	3.0	6
168	¹⁸F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 681-690.	1.0	29
169	68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. Nuclear Medicine Communications, 2008, 29, 415-417.	1.1	16
170	Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. Nuclear Medicine Communications, 2008, 29, 705-710.	1.1	8
171	Distal Esophagus: Evaluation with 18F-FDG PET/CT Fusion Imaging. , 2008, , 55-61.		0
172	18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo, 2008, 22, 513-7.	1.3	61
173	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica, 2007, 92, 50-55.	3.5	318
174	18F-DOPA PET and PET/CT. Journal of Nuclear Medicine, 2007, 48, 1577-1579.	5.0	120
175	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. Clinical Cancer Research, 2007, 13, 1322-1330.	7.0	126
176	Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nuclear Medicine Communications, 2007, 28, 547-553.	1.1	32
177	Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. Nuclear Medicine Communications, 2007, 28, 647-652.	1.1	14
178	Role of small animal PET in stimulating the development of new radiopharmaceuticals in oncology. Nuclear Medicine Communications, 2007, 28, 427-429.	1.1	7
179	Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. Nuclear Medicine Communications, 2007, 28, 473-477.	1.1	45
180	Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. Nuclear Medicine Communications, 2007, 28, 589-595.	1.1	168

#	Article	IF	Citations
181	Epithelial and Mesenchymal Tumor Compartments Exhibit In Vivo Complementary Patterns of Vascular Perfusion and Glucose Metabolism. Neoplasia, 2007, 9, 900-908.	5.3	24
182	Positron Emission Tomography and Thyroid Cancer. PET Clinics, 2007, 2, 295-304.	3.0	3
183	The Evolving Role of Positron Emission Tomography in Patients with Medullary Thyroid Carcinoma. PET Clinics, 2007, 2, 305-311.	3.0	3
184	11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World Journal of Surgical Oncology, 2007, 5, 68.	1.9	97
185	Performance evaluation of a small animal PET scanner. Spatial resolution characterization using 18F and 11C. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 215-218.	1.6	10
186	FDG small animal PET permits early detection of malignant cells in a xenograft murine model. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 755-762.	6.4	25
187	Role of small animal PET for molecular imaging in pre-clinical studies. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1819-1822.	6.4	13
188	11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1704-1705.	6.4	25
189	18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leukemia and Lymphoma, 2006, 47, 2096-2101.	1.3	54
190	Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. Leukemia and Lymphoma, 2006, 47, 1048-1052.	1.3	5
191	Role ofÂ18F-FDG-PET andÂPET/CT imaging inÂthyroid cancer. Biomedicine and Pharmacotherapy, 2006, 60, 409-413.	5.6	46
192	Clinical PET in oncology: not only FDG. Nuclear Medicine Communications, 2006, 27, 685-688.	1.1	4
193	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 525-531.	6.4	135
194	11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 453-459.	6.4	49
195	18F-DOPA PET/CT and neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 509-513.	6.4	23
196	Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nuclear Medicine Communications, 2005, 26, 689-694.	1.1	88
197	Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. Nuclear Medicine Communications, 2005, 26, 827-830.	1.1	31
198	18F-FDG PET in malignant lymphoma: significance of positive findings. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 749-756.	6.4	62

#	Article	IF	Citations
199	Value of PET-CT fusion imaging in avoiding potential pitfalls in the interpretation of 18F-FDG accumulation in the distal oesophagus. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 990-992.	6.4	14
200	Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. Blood, 2005, 106, 3492-3492.	1.4	0
201	Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. Journal of Nuclear Medicine, 2005, 46, 1642-9.	5.0	178
202	Role of18F-FDG PET for Evaluating Malignant Pleural Mesothelioma. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 149-154.	1.0	30
203	¹⁸F-FDG PET Early After Radiotherapy in Lymphoma Patients. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 606-612.	1.0	24
204	Scintigraphic Findings in Necrotizing Myopathy. Clinical Nuclear Medicine, 2003, 28, 118-120.	1.3	1
205	Somatostatin Receptor Scintigraphy for Bronchial Carcinoid Follow-Up. Clinical Nuclear Medicine, 2003, 28, 548-552.	1.3	32